The role of oxidative stress in the development of vascular cognitive disorders

Close metadata

Recommended articles:

Cognitive impairment in post-traumatic stress disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):69-74

Meta-analysis of randomized controlled trials of the effectiveness of Prospekta in the treatment of vascular cognitive impairment of varying severity. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):62-69

The randomized double-blind placebo-controlled study of efficacy and safety of mexidol in the complex therapy of ischemic stroke in the acute period. S.S. Korsakov Journal of Neurology and Psychiatry. 2006;(12-2):47-54

The role of biomarkers of endothelial dysfunction in predicting the progression of mild cognitive impairment in patients with cardiovascular risk factors. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):88-95

The effect of ethylmethylhydroxypyridine succinate on the parameters of chronic neuroinflammation and plastic processes in the brain of old rats during course of dexamethasone administration. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):115-121

Therapeutic and preventive effect of alpha-glutamyl-tryptophan on gastric mucosal lesions caused by non-steroidal anti-inflammatory drugs. An experimental study. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):25-34

Possibilities of using cytoprotectors in complex therapy of chronic coronary heart disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(4):410-419

Influence of cardiorespiratory training program on the intercellular adhesion molecule level in patients with postmastectomy syndrome. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(4):45-51

The role of mitochondrial dysfunction in the stabilization of the glaucomatous process. Russian Annals of Ophthalmology. 2024;(4):49-58

Determination of indications for antioxidant therapy at the stage of pregravidar preparation of patients with early fetal loss in anamnesis. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):66-70

Vascular cognitive impairment (VCI) is one of the most serious problems of clinical neurology, being the second most common cause of dementia. VCI covers a range of disorders in which vascular factors cause or contribute to cognitive decline. Among the main risk factors for VCI are old age and vascular factors, which lead to endothelial dysfunction and damage, which, in turn, can cause neurovascular dysfunction, increased permeability of the blood-brain barrier, and microvascular thrombosis. Oxidative stress is one of the most important mechanisms for the development of VCI that indicates the need for the use of agents with antioxidant activity. One of these drugs is ethylmethylhydroxypyridine succinate (mexidol). Mexidol is a drug with marked antioxidant and antihypoxic activities. The clinical efficacy of mexidol in relation to VCI has been demonstrated in many studies.

Keywords:

chronic cerebrovascular insufficiency

oxidative stress

vascular cognitive impairment

endothelial dysfunction

mexidol

Authors:

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

SPIN RSCI: 6775-0279
Scopus AuthorID: 6602240836
ORCID: 0000-0002-6327-3546

Received:

09.07.2020

Accepted:

10.07.2020

List of references:

Wolters FJ, Ikram MA. Epidemiology of Vascular Dementia. Arterioscler Thromb Vasc Biol. 2019;39(8):1542-1549. https://doi.org/10.1161/ATVBAHA.119.311908
Vinciguerra L, Lanza G, Puglisi V, Fisicaro F, Pennisi M, Bella R, Cantone M. Update on the Neurobiology of Vascular Cognitive Impairment: From Lab to Clinic. Int J Mol Sci. 2020;21(8):E2977. https://doi.org/10.3390/ijms21082977
Ramirez-Gomez L, Zheng L, Reed B, Kramer J, Mungas D, Zarow C, Vinters H, Ringman JM, Chui H. Neuropsychological Profiles Differentiate Alzheimer Disease from Subcortical Ischemic Vascular Dementia in an Autopsy-Defined Cohort. Dement Geriatr Cogn Disord. 2017;44(1-2):1-11. https://doi.org/10.1159/000477344
Flanagan M, Larson EB, Latimer CS, Cholerton B, Crane PK, Montine KS, White LR, Keene CD, Montine TJ. Clinical-pathologic correlations in vascular cognitive impairment and dementia. Biochim Biophys Acta. 2016;1862(5):945-951. https://doi.org/10.1016/j.bbadis.2015.08.019
O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST. Vascular cognitive impairment. Lancet Neurol. 2003;2(2):89-98. https://doi.org/10.1016/S1474-4422(03)00305-3
Sachdev P, Kalaria R, O’Brien J, Skoog I, Alladi S, Black SE, Blacker D, Blazer DG, Chen C, Chui H, Ganguli M, Jellinger K, Jeste DV, Pasquier F, Paulsen J, Prins N, Rockwood K, Roman G, Scheltens P; Internationlal Society for Vascular Behavioral and Cognitive Disorders. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218. https://doi.org/10.1097/WAD.0000000000000034
van der Flier WM, Skoog I, Schneider JA, Pantoni L, Mok V, Chen CLH, Scheltens P. Vascular cognitive impairment. Nat Rev Dis Primers. 2018;4:18003. https://doi.org/10.1038/nrdp.2018.3
Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689-701. https://doi.org/10.1016/S1474-4422(10)70104-6
Zijlmans JC, Daniel SE, Hughes AJ, Révész T, Lees AJ. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord. 2004;19(6):630-640. https://doi.org/10.1002/mds.20083
Mostile G, Nicoletti A, Cicero CE, Cavallaro T, Bruno E, Dibilio V, Luca A, Sciacca G, Raciti L, Contrafatto D, Chiaramonte I, Zappia M. Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism. Neurol Sci. 2016;37(4):591-595. https://doi.org/10.1007/s10072-016-2489-x
Stephan BC, Matthews FE, Ma B, Muniz G, Hunter S, Davis D, McKeith IG, Foster G, Ince PG, Brayne C. Alzheimer and vascular neuropathological changes associated with different cognitive States in a non-demented sample. J Alzheimers Dis. 2012;29(2):309-318. https://doi.org/10.3233/JAD-2011-110518
Tyas SL, Snowdon DA, Desrosiers MF, Riley KP, Markesbery WR. Healthy ageing in the Nun Study: Definition and neuropathologic correlates. Age Ageing. 2007;36:650-655. https://doi.org/10.1093/ageing/afm120
Skrobot OA, Attems J, Esiri M, Hortobagyi T, Ironside JW, Kalaria RN, King A, Lammie GA, Mann D, Neal J. Vascular cognitive impairment neuropathology guidelines (VCING): The contribution of cerebrovascular pathology to cognitive impairment. Brain J Neurol. 2016;139:2957-2969. https://doi.org/10.1093/brain/aww214
Pendlebury ST, Rothwell PM, Oxford Vascular Study. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study. Lancet Neurol. 2019;18(3):248-258. https://doi.org/10.1016/S1474-4422(18)30442-3
Gorelick PB, Counts SE, Nyenhuis D. Vascular cognitive impairment and dementia. Biochim Biophys Acta. 2016;1862(5):860-868. https://doi.org/10.1016/j.bbadis.2015.12.015
Khan A, Kalaria RN, Corbett A, Ballard C. Update on Vascular Dementia. J Geriatr Psychiatry Neurol. 2016;29(5):281-301. https://doi.org/10.1177/0891988716654987
Gorelick PB, Nyenhuis D; American Society of Hypertension Writing Group, Materson BJ, Calhoun DA, Elliott WJ, Phillips RA, Taler SJ, Townsend RR. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. J Am Soc Hypertens. 2012;6(5):309‐315. https://doi.org/10.1016/j.jash.2012.08.004
Cipollini V, Troili F, Giubilei F. Emerging Biomarkers in Vascular Cognitive Impairment and Dementia: From Pathophysiological Pathways to Clinical Application. Int J Mol Sci. 2019;20(11):E2812. https://doi.org/10.3390/ijms20112812
Park L, Anrather J, Girouard H, Zhou P, Iadecola C. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab. 2007;27(12):1908-1918. https://doi.org/10.1038/sj.jcbfm.9600491
Banko NS, McAlpine CS, Venegas-Pino DE, Raja P, Shi Y, Khan MI, Werstuck GH. Glycogen synthase kinase 3α deficiency attenuates atherosclerosis and hepatic steatosis in high fat diet-fed low density lipoprotein receptor-deficient mice. Am J Pathol. 2014;184(12):3394-3404. https://doi.org/10.1016/j.ajpath.2014.07.028
Luca A, Calandra C, Luca M. Gsk3 Signalling and Redox Status in Bipolar Disorder: Evidence from Lithium Efficacy. Oxid Med Cell Longev. 2016;3030547. https://doi.org/10.1155/2016/3030547
Toth P, Tarantini S, Csiszar A, Ungvari Z. Functional vascular contributions to cognitive impairment and dementia: mechanisms and consequences of cerebral autoregulatory dysfunction, endothelial impairment, and neurovascular uncoupling in aging. Am J Physiol Heart Circ Physiol. 2017;312(1):1-20. https://doi.org/10.1152/ajpheart.00581.2016
Luca M, Luca A, Calandra C. The Role of Oxidative Damage in the Pathogenesis and Progression of Alzheimer’s Disease and Vascular Dementia. Oxid Med Cell Longev. 2015;504678. https://doi.org/10.1155/2015/504678
Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, Schneider JA, Dichgans M. Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;73(25):3326-3344. https://doi.org/10.1016/j.jacc.2019.04.034
Parfenov VA, Ostroumova OD, Ostroumova TM, Kochetkov AI, Fateeva VV, Khacheva KK, Khakimova GR, Epstein OI. Vascular cognitive impairment: Pathophysiological mechanisms, insights into structural basis, and perspectives in specific treatments. Neuropsychiatr Dis Treat. 2019;15:1381-1402. https://doi.org/10.2147/NDT.S197032
Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci. 2013;5:17. https://doi.org/10.3389/fnagi.2013.00017
Castellazzi M, Trentini A, Romani A, Valacchi G, Bellini T, Bonaccorsi G, Fainardi E, Cavicchio C, Passaro A, Zuliani G. Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases. Int J Biochem Cell Biol. 2016;81:356-363. https://doi.org/10.1016/j.biocel.2016.06.008
Cervellati C, Trentini A, Romani A, Bellini T, Bosi C, Ortolani B, Zurlo A, Passaro A, Seripa D, Zuliani G. Serum paraoxonase and arylesterase activities of paraoxonase-1 (PON-1), mild cognitive impairment, and 2-year conversion to dementia: A pilot study. J Neurochem. 2015;135:395-401. https://doi.org/10.1111/jnc.13240
Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844-866. https://doi.org/10.1016/j.neuron.2013.10.008
Novak V, Hajjar I. The relationship between blood pressure and cognitive function. Nat Rev Cardiol. 2010;7:686-698. https://doi.org/10.1038/nrcardio.2010.161
Marchesi C, Paradis P, Schiffrin EL. Role of the rennin — angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2008;29:367-374. https://doi.org/10.1016/j.tips.2008.05.003
Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol. 2011;300:1566-1582. https://doi.org/10.1152/ajpheart.01310.2010
Gill R, Tsung A, Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radic Biol Med. 2010;48:1121-1132. https://doi.org/10.1016/j.freeradbiomed.2010.01.006
Carrano A, Hoozemans JJ, van der Vies SM, Rozemuller AJ, van Horssen J, de Vries HE. Amyloid beta induces oxidative stress-mediated blood — brain barrier changes in capillary amyloid angiopathy. Antioxid. Redox Signal. 2011;15:1167-1178. https://doi.org/10.1089/ars.2011.3895
Guo S, Kim WJ, Lok J, Lee SR, Besancon E, Luo BH, Stins MF, Wang X, Dedhar S, Lo EH. Neuroprotection via matrix — trophic coupling between cerebral endothelial cells and neurons. Proc Natl Acad Sci USA. 2008;105:7582-7587. https://doi.org/10.1073/pnas.0801105105
Sim FJ, Zhao C, Penderis J, Franklin RJ. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci. 2002;22:2451-2459. https://doi.org/10.1523/JNEUROSCI.22-07-02451.2002
Massaad CA, Klann E. Reactive oxygen species in the regulation of synaptic plasticity and memory. Antioxidants & Redox Signaling. 2011;14(10):2013-2054. https://doi.org/10.1089/ars.2010.3208
Chiang PL, Chen HL, Lu CH, Chen YS, Chou KH, Hsu TW, Chen MH, Tsai NW, Li SH, Lin WC. Interaction of systemic oxidative stress and mesial temporal network degeneration in Parkinson’s disease with and without cognitive impairment. J Neuroinflammation. 2018;15(1):281. https://doi.org/10.1186/s12974-018-1317-z
Black CN, Bot M, Scheffer PG, Cuijpers P, Penninx BW. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology. 2015;51:164-175. https://doi.org/10.1016/j.psyneuen.2014.09.025
Gudjoncik A, Guenancia C, Zeller M, Cottin Y, Vergely C, Rochette L. Iron, oxidative stress, and redox signaling in the cardiovascular system. Mol Nutr Food Res. 2014;58(8):1721-1738. https://doi.org/10.1002/mnfr.201400036
Islam MT. Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol Res. 2017;39(1):73-82. https://doi.org/10.1080/01616412.2016.1251711
Shchulkin AV. The effect of Mexidol on the development of the phenomenon of excitotoxicity of neurons in vitro. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;11(2):35-39. (In Russ.)
Shetekauri SA. Modern possibilities of antioxidant therapy and experience in the treatment of patients with chronic cerebrovascular insufficiency with mexidol. Bulletin of Experimental Biology and Medicine. 2006;1:156-15. (In Russ.)
Yanishevsky SN. The experience of using the drug «Mexidol» in the treatment of chronic cerebrovascular insufficiency in patients with stenosing-occlusive lesion of the main brachycephalic vessels. Bulletin of Experimental Biology and Medicine. 2006;1:159-163. (In Russ.)
Abramenko YuV. Assessment of the clinical efficacy, vasoactive and metabolic effects of Mexidol in elderly patients with discirculatory encephalopathy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2011;111(11):35-41. (In Russ.)
Sidenkova AP. Characteristics of anxiety in patients of older age groups with different types of mild cognitive disorder. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(11):52-57. (In Russ.) https://doi.org/10.17116/jnevro201711711145-50
Chukanova EI, Chukanova AS, Mamaeva KhI. The results of the study of the efficacy and safety of mexidol in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(2):71-74. (In Russ.) https://doi.org/10.17116/jnevro20151152171-74
Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(9):39-45. (In Russ.) https://doi.org/10.17116/jnevro201911909139
Shchepankevich LA, Nikolaev YuA, Dolgova NA. Optimization of hypolipidemic therapy in ischemic stroke and diabetes mellitus patients. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(2):42-45. (In Russ.) https://doi.org/10.17116/jnevro20161162142-45
Tanashyan MM, Lagoda OV, Antonova KV. Chronic cerebrovascular diseases associated with metabolic syndrome: new treatment approaches. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(11):21-26. (In Russ.)

Close metadata